W. McCaskill-Stevens

发表

Barriers to racial/ethnic minority application and competition for NIH research funding.

V. Shavers, P. Fagan, Deirdre Lawrence, 2005, Journal of the National Medical Association.

W. McCaskill-Stevens, E. Trimble, L. Minasian, 2009, The oncologist.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Debora Fumagalli, Norman Wolmark, Soonmyung Paik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study.

W. McCaskill-Stevens, M. Daly, C. Holmberg, 2015, Sociology of health & illness.

Adjuvant chemotherapy for node-negative breast cancer.

W. McCaskill-Stevens, G. Sledge, 1992, Cancer investigation.

DeImplementing Ineffective and Low-Value Clinical Practices: Research and Practice Opportunities in Community Oncology Settings.

David A. Chambers, B. Kramer, W. McCaskill-Stevens, 2021, JNCI cancer spectrum.

Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience.

W. McCaskill-Stevens, L. Minasian, M. M. McKinney, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings.

W. McCaskill-Stevens, J. Lampe, M. Messina, 2006, Journal of the National Cancer Institute.

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

S. Reis, W. McCaskill-Stevens, S. Lippman, 2006 .

Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.

W. McCaskill-Stevens, J. Bryant, D. Wickerham, 2004, Journal of the National Cancer Institute.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

B. Kramer, A. Kaluzny, W. McCaskill-Stevens, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.

Carol L. Brown, W. McCaskill-Stevens, C. Somkin, 2015, Journal of oncology practice.

COVID-19, Social Justice, and Clinical Cancer Research

W. McCaskill-Stevens, J. Doroshow, M. Mooney, 2020, Journal of the National Cancer Institute.

Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial

W. McCaskill-Stevens, L. Minasian, J. Probstfield, 2010, Clinical trials.

Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association.

W. McCaskill-Stevens, A. Marcus, R. Morgan, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement.

Nadine J Barrett, W. McCaskill-Stevens, E. Yang, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.

W. McCaskill-Stevens, R. Enos, A. Denicoff, 2014, Journal of oncology practice.

Evolution of Cancer Care Delivery Research in the NCI Community Oncology Research Program.

W. McCaskill-Stevens, A. Geiger, A. O'Mara, 2019, Journal of the National Cancer Institute.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction

W. McCaskill-Stevens, D. Wickerham, A. Fagerlin, 2017, Cancer Prevention Research.

Challenges in ductal carcinoma in situ risk communication and decision‐making

J. Elmore, W. McCaskill-Stevens, S. Schnitt, 2012, CA: a cancer journal for clinicians.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

W. McCaskill-Stevens, J. Costantino, D. Wickerham, 2010, Journal of the National Cancer Institute. Monographs.

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

W. McCaskill-Stevens, T. Julian, J. Costantino, 2013, Breast Cancer Research and Treatment.

Establishing a Primary Care Alliance for Conducting Cancer Prevention Clinical Research at Community Sites

W. McCaskill-Stevens, L. Ford, B. McAneny, 2021, Cancer Prevention Research.

Use of a clinical trial screening tool to enhance patient accrual

W. McCaskill-Stevens, D. S. St Germain, 2021, Cancer.

Chemoprevention for breast cancer: overcoming barriers to treatment.

W. McCaskill-Stevens, N. Davidson, A. Brewster, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Reporting of health‐related quality of life endpoints in National Cancer Institute–supported cancer treatment trials

W. McCaskill-Stevens, L. Minasian, A. Denicoff, 2020, Cancer.

A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.

W. McCaskill-Stevens, G. Sledge, R. Hoffman, 1996, Blood.

Cooperative Group Trials in the Community Setting.

W. McCaskill-Stevens, N. Petrelli, James Lloyd Wade, 2015, Seminars in oncology.

Creating a “culture of research” in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program

W. McCaskill-Stevens, H. Zaren, A. Denicoff, 2015, Clinical trials.

Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.

Danielle M. Enserro, W. McCaskill-Stevens, A. Taghian, 2020, Gynecologic oncology.

Pilot Trial of Alternating Paclitaxel and Doxorubicin in Advanced Breast Cancer

D. Neuberg, W. McCaskill-Stevens, G. Sledge, 1997 .

The NCI Community Oncology Research Program: what every clinician needs to know.

W. McCaskill-Stevens, R. Lilenbaum, A. Lyss, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.

D. Neuberg, W. McCaskill-Stevens, G. Sledge, 1994, Seminars in oncology.

Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.

S. Reis, W. McCaskill-Stevens, L. Ford, 2015 .

Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

S. Chanock, M. Knopp, W. McCaskill-Stevens, 2021 .

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Norman Wolmark, Scott M Lippman, S. Reis, 2006, JAMA.

Participation of Minorities in Cancer Research

W. McCaskill-Stevens, A. Giuliano, R. Ho, 2000 .

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

Joseph P. Costantino, V. Craig Jordan, Victor G. Vogel, 2010, Cancer Prevention Research.

Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program

Ken Resnicow, Ronald S Go, Aisha T. Langford, 2014, Cancer.

Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community.

W. McCaskill-Stevens, B. Weiner, R. Zon, 2016, Journal of oncology practice.

Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP).

W. McCaskill-Stevens, M. Krasna, H. Zaren, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients

W. McCaskill-Stevens, B. Freidlin, J. Doroshow, 2020 .

National Cancer Institute--supported cancer chemoprevention research: coming of age.

W. McCaskill-Stevens, S. Lippman, E. Hawk, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SI RLTD: Risk Scores and Decision Making: The Anatomy of a Decision to Reduce Breast Cancer Risk.

W. McCaskill-Stevens, M. Daly, C. Holmberg, 2010, Journal of nursing and healthcare of chronic illness.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank

B. Kramer, W. McCaskill-Stevens, L. Ford, 2016, Cancer Prevention Research.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

M. Gail, W. McCaskill-Stevens, G. Anderson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multidisciplinary meeting on male breast cancer: summary and research recommendations.

J. Bergh, W. McCaskill-Stevens, G. Hortobagyi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tomosynthesis mammographic Imaging Screening Trial (TMIST): An Invitation and Opportunity for the National Medical Association Community to Shape the Future of Precision Screening for Breast Cancer.

W. McCaskill-Stevens, Cecilia Lee, 2020, Journal of the National Medical Association.

A Report of the Women's Health Congress Workshop on The Health of Women of Color: A Critical Intersection at the Corner of Sex/Gender and Race/Ethnicity

W. McCaskill-Stevens, J. Clayton, Jennifer L. Plank-Bazinet, 2016, Journal of women's health.

Promoting cancer screening among the first-degree relatives of breast and colorectal cancer patients: the design of two randomized trials.

W. McCaskill-Stevens, D. Ahnen, N. Calonge, 1999, Preventive medicine.

Projecting individualized absolute invasive breast cancer risk in African American women.

Melissa Bondy, Giske Ursin, Mitchell H Gail, 2007, Journal of the National Cancer Institute.

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.

W. McCaskill-Stevens, G. Sledge, R. Seshadri, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Race and the Prognostic Influence of p53 in Women with Breast Cancer

W. McCaskill-Stevens, S. Gehlert, J. Dignam, 2012, Annals of Surgical Oncology.

Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

J. Griggs, C. Flowers, W. McCaskill-Stevens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translating research into evidence‐based practice

A. Kaluzny, W. McCaskill-Stevens, L. Minasian, 2010, Cancer.

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

David J. Sims, R. Gray, A. Iafrate, 2020, Journal of the National Cancer Institute.

Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients

W. McCaskill-Stevens, E. Pisano, L. Minasian, 2003, CA: a cancer journal for clinicians.

Chemotherapy for Breast Cancer: How Are We Doing? Can We Do Better?

W. McCaskill-Stevens, G. Sledge, 1996 .

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.

W. McCaskill-Stevens, J. Krischer, M. Guglin, 2019, Journal of the American College of Cardiology.

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.

J. Olson, R. Gray, W. McCaskill-Stevens, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Mitch Dowsett, Marion Procter, Brian Leyland-Jones, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges and recommendations for advancing the state‐of‐the‐science of quality of life assessment in symptom management trials

W. McCaskill-Stevens, L. Minasian, A. O'Mara, 2007, Cancer.

Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

W. McCaskill-Stevens, S. Lippman, F. Khuri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results

R. Gray, W. McCaskill-Stevens, T. Whelan, 2019, General Session Abstracts.

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

R. Gelber, W. McCaskill-Stevens, P. Francis, 2009, Breast Cancer Research and Treatment.

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.

Lori M. Minasian, Laura A. Levit, Wendy Demark-Wahnefried, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OP-JNCI190248 557..561

W. McCaskill-Stevens, A. Geiger, A. O'Mara, 2020 .

Impact of comorbidity and age on treatment choice among men with localized prostate cancer.

W. McCaskill-Stevens, P. Pinsky, R. Grubb, 2019, Journal of Clinical Oncology.

Chemoprevention for breast cancer.

W. McCaskill-Stevens, F. Cardoso, P. Dinh, 2012, Cancer treatment reviews.

Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.

J. Manola, W. McCaskill-Stevens, L. Minasian, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Sowmya R. Rao, M. Gail, W. McCaskill-Stevens, 2003, Journal of the National Cancer Institute.

Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

J. Griggs, C. Flowers, W. McCaskill-Stevens, 2017, Cancer research.

Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute

J. Griggs, C. Flowers, W. McCaskill-Stevens, 2017, CA: a cancer journal for clinicians.

Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors.

W. McCaskill-Stevens, A. Giuliano, T. E. Prewitt, 2000, Annals of epidemiology.

Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.

Christine M. Gunn, W. McCaskill-Stevens, A. Fagerlin, 2017, Patient education and counseling.

My Lived Experiences Are More Important Than Your Probabilities

Erika A. Waters, W. McCaskill-Stevens, M. Daly, 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

Breast cancer prevention: the next steps.

W. McCaskill-Stevens, L. Ford, B. Dunn, 2000, European journal of cancer.

A phase i trial of subcutaneous (SC) BB-10010 in breast. Cancer patients (PTS) receiving high-dose cyclophosphamide (C)

W. McCaskill-Stevens, H. Broxmeyer, M. Gordon, 1996 .

p53 as a Marker of Prognosis in African-American Women with Breast Cancer

W. McCaskill-Stevens, S. Gehlert, J. Dignam, 2010, Annals of Surgical Oncology.

Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer.

W. McCaskill-Stevens, H. Zaren, B. Lukaszczyk, 2007 .

p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer

W. McCaskill-Stevens, H. Zaren, B. Lukaszczyk, 2006 .

Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1

Christine M. Gunn, W. McCaskill-Stevens, A. Fagerlin, 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

A critical review of the enrollment of black patients in cancer clinical trials.

W. McCaskill-Stevens, S. Swain, J. Ford, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative.

W. McCaskill-Stevens, A. Marcus, H. Pinto, 2000, Annals of epidemiology.

Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment

W. McCaskill-Stevens, L. Fashoyin-Aje, A. Ramirez, 2023, JCO oncology practice.

Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.

W. McCaskill-Stevens, L. Fashoyin-Aje, A. Ramirez, 2022, Journal of Clinical Oncology.

The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

W. McCaskill-Stevens, K. Weinfurt, M. Fouad, 2013, Journal of oncology practice.

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

E. Perez, W. McCaskill-Stevens, J. Sloan, 2014 .

The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

R. Gelber, M. Buyse, W. McCaskill-Stevens, 2008 .

Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes?

W. McCaskill-Stevens, J. Abrams, 2011, Journal of the National Cancer Institute.

Breast Cancer Risk Assessments Comparing Gail and CARE Models in African‐American Women

W. McCaskill-Stevens, K. Makambi, L. Adams-Campbell, 2009, The breast journal.

Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.

Linda K. Han, C. Gatsonis, W. McCaskill-Stevens, 2019, JAMA oncology.